#Switzerland #Basel #Jungbunzlauer #Tricalcium Citrate #TCC TB

Jungbunzlauer's Tricalcium Citrate Surpasses Expectations in Tablet Production

In a significant advancement for the pharmaceutical and nutraceutical sectors, Jungbunzlauer, recognized globally for its high-quality, sustainable ingredients, has partnered with Professor Karl Wagner from the University of Bonn to unveil compelling research on its tricalcium citrate product, TCC TB. This innovation is set to redefine the standards for direct compression in tablet manufacturing, proving essential for efficient and high-quality production.

Markus Gerhart, Senior Director Category Lead Minerals Solutions at Jungbunzlauer, emphasized the importance of their collaboration with Professor Wagner's research team. He stated, "This partnership underscores our commitment to rigorous science, innovation, and product excellence. Through validated research, we're proud to demonstrate that our TCC TB delivers reliable performance in direct compression, helping our customers achieve efficiency, quality, and confidence."

One of the prevailing challenges in tablet production is the requirement for excipients with exceptional flow and compactibility. As direct compression continues to gain popularity due to its efficiency and compatibility with sensitive ingredients, the quality of excipients has become more vital than ever. The results from this recent study confirm that TCC TB not only delivers excellent flowability but also maintains robust tablet strength, even under low compression forces. It ensures rapid disintegration, making it suitable for various complex formulations, including minitablets, moisture-sensitive active pharmaceutical ingredients (APIs), and botanical extracts.

TCC TB is produced from the complete neutralization of citric acid with a high purity calcium source, ensuring its status as a vegan product, allergen-free, and non-GMO. It also adheres to stringent industry standards such as USP, FCC, and EU regulations. This makes TCC TB a versatile choice for formulators seeking reliable excipients in their products.

The findings from this study will be prominently featured at the CPHI Global event taking place at Messe Frankfurt from October 28-30, 2025. Attendees are encouraged to engage with Jungbunzlauer representatives to delve deeper into the study findings and discover how TCC TB can assist with their next formulation challenges.

Jungbunzlauer has established itself as a leader in producing sustainable ingredients sourced from nature, actively supporting industries ranging from food and beverage to nutrition and personal care. With over 150 years of dedication, the company has built a reputation for developing naturally better ingredients that enhance everyday life. Its commitment to innovation is evident in its diverse portfolio, which includes texturants, acidulants, sweeteners, minerals, and tailored solutions designed to meet evolving customer needs.

Headquartered in Basel, Switzerland, and equipped with advanced facilities, including large-scale fermentation operations across Europe and North America, Jungbunzlauer serves more than 130 countries worldwide. The company has grown into a CHF 1.3 billion entity, powered by nearly 1,400 dedicated professionals committed to advancing a healthier, more sustainable future. To learn more about Jungbunzlauer and its products, visit their official website.